Am­gen touts new da­ta for obe­si­ty drug Mar­i­Tide, mov­ing rapid­ly in­to Phase 3 work

Am­gen said that an in­ter­im look at a Phase 2 tri­al of its an­ti-obe­si­ty drug Mar­i­Tide had left the com­pa­ny “very en­cour­aged,” and it planned to rapid­ly move for­ward with a fi­nal-stage pro­gram as well as boost man­u­fac­tur­ing ca­pac­i­ty for the ex­per­i­men­tal drug.

“We are con­fi­dent in Mar­i­Tide’s dif­fer­en­ti­at­ed pro­file and be­lieve it will ad­dress im­por­tant un­met med­ical need,” CEO Bob Brad­way said on a call Thurs­day with in­vestors af­ter Am­gen re­leased first-quar­ter re­sults. Brad­way said the com­pa­ny was plan­ning a broad Phase 3 pro­gram in obe­si­ty, di­a­betes and obe­si­ty-re­lat­ed con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER